The company has also announced that under the direction of the Scripps Advanced Clinical Trials center, it is sponsoring a 6000 patient, multi-center trial, called GRAVITAS (Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety) to establish platelet function testing with VerifyNow as the standard of care.
Steven Frankel, CEO of Accumetrics, said: “Completion of this $28.8 million financing enables us to initiate the GRAVITAS study and positions the company for commercial success. We believe the results of the GRAVITAS trial will establish the VerifyNow system as a routine diagnostic tool.”